Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
 
Table of Contents

EXHIBIT INDEX
 
         
Exhibit
   
Number
 
Description
 
  1 .1   Form of Underwriting Agreement
  3 .1(1)   Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect
  3 .2   Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect
  3 .3(3)   Form of Amended and Restated Certificate of Incorporation of the Registrant, to be in effect upon completion of the offering
  3 .4(1)   Bylaws of the Registrant, as currently in effect
  3 .5(3)   Form of Amended and Restated Bylaws of the Registrant, to be in effect upon completion of the offering
  4 .1   Form of the Registrant’s Common Stock Certificate
  4 .2(1)   Second Amended and Restated Investors’ Rights Agreement dated November 20, 2006
  5 .1   Opinion of Latham & Watkins LLP
  10 .1(3)   Form of Director and Executive Officer Indemnification Agreement
  10 .2(3)   Form of Executive Officer Employment Agreement
  10 .3#(1)   2004 Stock Plan and forms of option agreements thereunder
  10 .4#(3)   Independent Director Compensation Policy
  10 .5#(3)   2007 Equity Incentive Award Plan and forms of option and restricted stock agreements thereunder
  10 .6(1)   Lease dated September 22, 2006 by and between the Registrant and Prentiss/Collins Del Mar Heights LLC
  10 .7†   License Agreement dated June 27, 2003 by and between the Registrant and Oregon Health & Science University
  10 .8†(1)   Amendment to License Agreement dated June 27, 2003 by and between the Registrant and Oregon Health & Science University
  10 .9†(1)   Letter Agreement Amendment to License Agreement dated June 27, 2003 by and between the Registrant and Oregon Health & Science University
  10 .10†   License Agreement dated March 31, 2004 by and between the Registrant and Duke University
  10 .11†(1)   Amendment No. 1 to License Agreement dated March 31, 2004 by and between the Registrant and Duke University
  10 .12†(1)   Amendment No. 2 to License Agreement dated March 31, 2004 by and between the Registrant and Duke University
  10 .13†   License Agreement dated June 1, 2004 by and between the Registrant and Lee G. Dante, M.D.
  10 .14†   License Agreement dated January 3, 2005 by and between the Registrant and Cypress Bioscience, Inc.
  10 .15(1)   Credit and Security Agreement dated December 15, 2006 by and between the Registrant and Merrill Lynch Capital
  10 .16(1)   Settlement Agreement dated December 14, 2006 by and among the Registrant, Duke University, Elan Corporation, plc, Elan Pharma International Ltd., Elan Pharmaceuticals, Inc., Eisai, Inc., Eisai Co., Ltd. and Julianne E. Jennings
  10 .17#(1)   Consulting Agreement dated February 1, 2005 by and between the Registrant and Eckard Weber, M.D.
  10 .18#(1)   Consulting Agreement dated January 14, 2005 by and between the Registrant and John Crowley
  10 .19(2)   Consulting Agreement dated December 9, 2005 by and between the Registrant and PharmaDirections, Inc.
  10 .20(2)   Letter Agreement Amendment to Consulting Agreement dated December 9, 2005 by and between the Registrant and PharmaDirections, Inc.
  10 .21   Research Agreement dated August 6, 2006 by and between the Registrant and Oregon Health & Science University
  10 .22   Master Agreement for Pharmaceutical Development Services dated February 16, 2007 by and between Registrant and Patheon Pharmaceuticals Inc.
  23 .1   Consent of Ernst & Young LLP, independent registered public accounting firm
  23 .2   Consent of Latham & Watkins LLP (included in Exhibit 5.1)
  24 .1(1)   Power of Attorney (See page II-5)
 
* To be filed by amendment.
 
(1) Filed with the Registrant’s Registration Statement on Form S-1 on December 19, 2006.
 
(2) Filed with Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 on January 23, 2007.
 
(3) Filed with Amendment No. 2 to the Registrant’s Registration Statement on Form S-1 on February 16, 2007.
 
Confidential treatment has been requested for portions of this exhibit. These portions have been omitted from the Registration Statement and submitted separately to the Securities and Exchange Commission.
 
# Indicates management contract or compensatory plan.